William Blair analyst Brandon Vazquez has maintained their bullish stance on IRTC stock, giving a Buy rating on August 21.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brandon Vazquez has given his Buy rating due to a combination of factors that highlight the potential for sustained growth at Irhythm Technologies. A key takeaway from the discussions with the company’s leadership during the West Coast Field Trip was the strong performance in the second quarter, which was broad-based across their portfolio. This momentum is expected to continue, particularly with large accounts that have recently begun utilizing all Zio services, including patches and software, from the outset.
Furthermore, the faster-than-anticipated ramp-up of these accounts, coupled with the potential for signing additional accounts in the near future, bolsters confidence in the company’s growth trajectory. The integration with electronic health records (EHR), innovative partner channels, and the anticipated launch of Zio MCT in 2026 are additional factors that position Irhythm Technologies well to meet growth expectations. With the stock trading at seven times the projected 2026 sales, Vazquez maintains an optimistic outlook, supporting his Buy rating.
According to TipRanks, Vazquez is an analyst with an average return of -0.4% and a 48.08% success rate. Vazquez covers the Healthcare sector, focusing on stocks such as PROCEPT BioRobotics, Neogen, and Elanco Animal Health.
In another report released on August 21, Citi also maintained a Buy rating on the stock with a $183.00 price target.